Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.27 USD | +3.83% | -2.52% | -0.21% |
Feb. 27 | Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance | MT |
Feb. 27 | Transcript : Ligand Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 27, 2024 |
Financials (USD)
Sales 2024 * | 137M | Sales 2025 * | 158M | Capitalization | 1.26B |
---|---|---|---|---|---|
Net income 2024 * | 28M | Net income 2025 * | 52M | EV / Sales 2024 * | 9.19 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8 x |
P/E ratio 2024 * |
42.6
x | P/E ratio 2025 * |
24.9
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.16% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | +3.83% | ||
1 week | -2.52% | ||
Current month | -10.18% | ||
1 month | -20.10% | ||
3 months | -1.40% | ||
6 months | +15.94% | ||
Current year | -0.21% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John W. Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 26 M€ | -0.05% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 71.27 | +3.83% | 191,807 |
24-03-26 | 68.64 | -0.88% | 107,915 |
24-03-25 | 69.25 | -2.46% | 107,055 |
24-03-22 | 71 | -2.69% | 67,489 |
24-03-21 | 72.96 | -0.21% | 91,154 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.21% | 1.26B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.79% | 210B | |
+1.00% | 210B | |
-6.69% | 201B | |
-3.51% | 157B |